Lawsonia intracellularis vaccines

An immunogenic composition consisting of a first polypeptide having an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:

• 1, 2, 3, 5, 7, 9, 10, and 11;
• a second polypeptide having an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:
• 12 and 13;
• one or more antigenic components of Mycoplasma hyopneumoniae Erysipelas spp. salmonella, Haemophilus parasuis, Clostridium spp. Streptococcus suis, Brachyspira spp. Bordetella, Pasteurella, Escherichia coli (E. coli), Coronavirus, Parvovirus, porcine reproductive and respiratory syndrome virus (PRRS), porcine circovirus (PCV), or swine influenza virus (SIV);
• and one or more pharmaceutically acceptable components selected from the group consisting of an appropriate pharmaceutical carrier and a pharmaceutically acceptable adjuvant.

An immunogenic composition consisting of one or more polypeptides having an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:

• 1, 2, 3, 5, 7, 9, 10, and 11;
• one or more polypeptides having an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:
• 12 and 13;
• and one or more pharmaceutically acceptable components selected from the group consisting of an appropriate pharmaceutical carrier and a pharmaceutically acceptable adjuvant.

An immunogenic composition consisting of one or more polypeptides having an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:

• 1, 2, 3, 5, 7, 9, 10, and 11;
• one or more polypeptides having an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:
• 12 and 13;
• and one or more antigenic components of Mycoplasma hyopneumoniae Erysipelas spp, salmonella, Haemophilus parasuis, Clostridium spp. Streptococcus suis, Brachyspira spp. Bordetella, Pasteurella, Escherichia coli (E. coli), Coronavirus, Parvovirus, porcine reproductive and respiratory syndrome virus (PRRS), porcine circovirus (PCV), or swine influenza virus (SIV);
• and one or more pharmaceutically acceptable components selected from the group consisting of an appropriate pharmaceutical carrier and a pharmaceutically acceptable adjuvant.